Home/Pipeline/Spritam (levetiracetam)

Spritam (levetiracetam)

Epilepsy

ApprovedActive

Key Facts

Indication

Epilepsy

Phase

Approved

Status

Active

Company

Aprecia Pharmaceuticals

About Aprecia Pharmaceuticals

Aprecia Pharmaceuticals is the global leader in applying binder jet 3D printing technology to pharmaceutical manufacturing, holding a foundational IP position with 126 granted patents. The company achieved a historic milestone with the FDA approval and commercialization of Spritam, a high-dose, rapidly disintegrating tablet, validating its platform. Operating as a private, revenue-generating company, Aprecia offers end-to-end services from formulation development to commercial-scale cGMP production for partners. Its business model centers on leveraging its proprietary 3DP platform to solve complex drug delivery challenges for the pharmaceutical industry.

View full company profile

Other Epilepsy Drugs

Drug	Company	Phase	Status
ADX71149 (mGlu2 PAM)	Addex Therapeutics	Phase 2	Active (with Janssen)
TRV045	Trevena	Phase 1	Active
SAGE-324	Sage Therapeutics	Preclinical	Research
Motpoly XR™	Aucta Pharmaceuticals	Not Specified (Likely Phase 3/NDA)	Active
ADB-104	Adolore BioTherapeutics	Pre-clinical	Active
Not Publicly Disclosed	Cerecin	Phase 2	Active
eTNS Platform	NeuroSigma	Unknown	Active
NPT 2042	NeuroPro Therapeutics	Phase 2	Active
Perampanel	Ark Diagnostics	In Development	Active
NeuroAccess Platform	Cordance Medical	Pre-clinical/Research	Active
Epilepsy Program	Current Surgical	Research	Active
GABA-A PAM for Epilepsy	Modulate Bio	Preclinical	Active